OPERA

Oligonucleotide compounds being a component in pharmaceutical preparations for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; RNA compounds being a component in pharmaceutical preparations for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; RNA therapeutics for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; Nucleic acid therapeutics for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; Oligonucleotide compounds being a component in pharmaceutical preparations for use in RNA editing; Oligonucleotide compounds being a component in pharmaceutical preparations for use in base editing; Oligonucleotide compounds being a component in pharmaceutical preparations for use as RNA therapeutic for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; Oligonucleotide compounds that facilitate the editing of RNA base; Pharmaceuticals, medicines, biologics, biotherapeutics, biosimilars and therapeutics, namely, nucleic acid therapeutics for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; pharmaceuticals, namely, bio-pharmaceutical preparations for the treatment of rare diseases

Custom manufacture of oligonucleotides or RNAs for use in genetic research, pharmaceutical therapies, medical research and treatment of various conditions and disorders